CNS Drugs

, Volume 15, Issue 7, pp 537–551 | Cite as

Bodyweight Gain Associated with Atypical Antipsychotics

Epidemiology and Therapeutic Implications
  • James M. Russell
  • Joan A. Mackell
Review Article


Atypical antipsychotic medications are associated with different adverse effects and efficacy profiles compared with conventional antipsychotics (i.e. less extrapyramidal symptoms, improved efficacy against negative symptoms and cognitive deficits, and most often a greater ability to improve patients’ quality of life). However, the atypical antipsychotics may be associated with clinically significant bodyweight gain, increasing the risk of medical comorbidity, including diabetes mellitus, hypertension, cardiovascular disease and hyperlipidaemia.

This literature review assesses the various bodyweight gain liabilities associated with atypical antipsychotics, as well as the effects of bodyweight gain on quality of life. The issue of prevention and management of this often neglected adverse effect is also examined.

Most studies reviewed indicate that clozapine and olanzapine are associated with more bodyweight gain than the other atypical antipsychotics. There are potential factors that place certain patients at greater risk for bodyweight gain, including low pretreatment body mass index, young age and being of female gender. Furthermore, bodyweight gain associated with the use of atypical anti-psychotics has been reported to be associated with clinical improvement, although this has not been substantiated widely. It is unclear whether increased medical comorbidity, including diabetes mellitus, coronary artery disease and/or elevated triglyceride levels, is secondary to the bodyweight gain associated with atypical antipsychotics, or the result of the agents themselves.

A patient’s quality of life may be greatly affected by excessive bodyweight gain; either by increased comorbid medical illness, an increased relapse rate associated with noncompliance, or the social stigma associated with being obese. However, most studies reveal that treatment with atypical antipsychotic medications is associated with improved quality of life compared with that achieved with conventional antipsychotic medications.

Because bodyweight is an important health risk associated with atypical antipsychotics, prevention and effective management of bodyweight are paramount in preventing comorbid medical illness, relapse and possible noncompliance.


Haloperidol Clozapine Risperidone Olanzapine Quetiapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Supported by an unrestricted educational grant from Pfizer Inc. Dr Russell has served as a consultant to Abbott Laboratories, Bristol Myers Squibb, Janssen Pharmaceutica, MEDSTAT and Pfizer. He has received grant support from Abbott Laboratories, Bristol Myers Squibb, Eli Lilly, Pfizer, NARSAD and the John Sealy Endowment for Medical Research.


  1. 1.
    Masand PS. Weight gain associated with atypical antipsychotics. J Psychotic Dis Rev Comment 1998; II(3): 4–6Google Scholar
  2. 2.
    Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 Suppl. 11: 40–5Google Scholar
  3. 3.
    Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 Suppl. 10: 55–62Google Scholar
  4. 4.
    Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997; 48: 1137–9PubMedGoogle Scholar
  5. 5.
    Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997; 4(5): 255–71PubMedCrossRefGoogle Scholar
  6. 6.
    Baldessarini R, Frankenberg F. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746–54PubMedCrossRefGoogle Scholar
  7. 7.
    Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry 1998; 59 Suppl. 12: 3–9Google Scholar
  8. 8.
    Juul Povlsen U, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176–85PubMedCrossRefGoogle Scholar
  9. 9.
    Brady KT. Weight gain associated with psychotropic drugs. South Med J 1989; 82(5): 611–7PubMedCrossRefGoogle Scholar
  10. 10.
    Leadbetter R, Shutty M, Pavalonis D. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149(1): 68–72PubMedGoogle Scholar
  11. 11.
    Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55:9 Suppl. B: 157–60PubMedGoogle Scholar
  12. 12.
    Heimberg C, Gallacher F, Gur R, et al. Diet and gender moderate clozapine-related weight gain. Hum Psychopharmacol 1995; 10: 367–71CrossRefGoogle Scholar
  13. 13.
    Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5: 437–40PubMedGoogle Scholar
  14. 14.
    Brecher M, Geller W Weight gain with risperidone. J Clin Psychopharmacol 1997; 17: 435–6PubMedCrossRefGoogle Scholar
  15. 15.
    Briffa D, Meehan T. Weight changes during clozapine treatment. Aust N Z J Psychiatry 1998; 32: 718–21PubMedCrossRefGoogle Scholar
  16. 16.
    Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8: 151–9PubMedCrossRefGoogle Scholar
  17. 17.
    Gupta S, Droney T, Al-Samarrai S. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999; 19: 273–4PubMedCrossRefGoogle Scholar
  18. 18.
    Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156(11): 1686–96PubMedGoogle Scholar
  19. 19.
    Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60 Suppl. 21: 16–9Google Scholar
  20. 20.
    Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatr Ann 1999; 29(10): 580Google Scholar
  21. 21.
    Taylor DM, McAskill R. Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr Scand 2000; 101: 416–32PubMedCrossRefGoogle Scholar
  22. 22.
    Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Drug Saf 1996; 14(5): 329–42PubMedCrossRefGoogle Scholar
  23. 23.
    Lamberti JS, Bellnier R, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149(5): 689–90PubMedGoogle Scholar
  24. 24.
    Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry 1990; 147: 503–4PubMedGoogle Scholar
  25. 25.
    Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54(549): 557Google Scholar
  26. 26.
    Masand PS. Weight gain and antipsychotic medications. JCP Visuals: J Clin Psychiatry 1999; Jan; 1–8Google Scholar
  27. 27.
    Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6): 358–63PubMedCrossRefGoogle Scholar
  28. 28.
    Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58Suppl. 10: 13–7PubMedGoogle Scholar
  29. 29.
    Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60(11): 767–70PubMedCrossRefGoogle Scholar
  30. 30.
    Bray GA. Complications of obesity. Ann Intern Med 1985; 103: 1052–62PubMedGoogle Scholar
  31. 31.
    Garfinkel L. Overweight and cancer. Ann Intern Med 1985; 103: 1034–6PubMedGoogle Scholar
  32. 32.
    Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17(9): 961–9PubMedCrossRefGoogle Scholar
  33. 33.
    Fleischhacker W, Meise U, Gunther V. Compliance with anti-psychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89: 11–5Google Scholar
  34. 34.
    Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481–6PubMedGoogle Scholar
  35. 35.
    Allison DB, Pi-Sunyer FX. Obesity treatment: examining the premises. Endocr Pract 1995; 1(5): 353–64PubMedGoogle Scholar
  36. 36.
    Fulton JE, Shekelle RB. Cigarette smoking, weight gain, and coronary mortality: results from the Chicago Western Electric study. Circulation 1997; 96(5): 1438–44PubMedCrossRefGoogle Scholar
  37. 37.
    Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277(19): 1539–45PubMedCrossRefGoogle Scholar
  38. 38.
    Zoler ML. Antipsychotics linked to weight gain, diabetes. Clin Psychiatry News 1999; Feb; 27(2): 20Google Scholar
  39. 39.
    Masand PS. Relative weight gain among antipsychotics. J Clin Psychiatry 1999; 60: 706–7PubMedCrossRefGoogle Scholar
  40. 40.
    Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999; 60 Suppl. 21: 5–9Google Scholar
  41. 41.
    Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079–81PubMedGoogle Scholar
  42. 42.
    McKee HA, D’Arcy PF, Wilson PJK. Diabetes and schizophrenia — a preliminary study. J Clin Hosp Pharm 1986; 11: 297–9PubMedGoogle Scholar
  43. 43.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183–97Google Scholar
  44. 44.
    Carson WH, Forbes RA. Letters to the editor. Am J Psychiatry 1990; 147: 1694Google Scholar
  45. 45.
    John JP, Chengappa KNR, Baker RW. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995; 7: 119–25PubMedCrossRefGoogle Scholar
  46. 46.
    Jalenques Y, Tauveron Y, Albuissan E, et al. Weight gain as a predictor of long-term clozapine efficacy. CNS Drugs 1996; 12: 16–25Google Scholar
  47. 47.
    Bustillo JR, Buchanan RW, Irish D, et al. Differential effects of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153: 817–9PubMedGoogle Scholar
  48. 48.
    Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155: 499–504PubMedGoogle Scholar
  49. 49.
    Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry 1998; 43: 520–4PubMedCrossRefGoogle Scholar
  50. 50.
    Kraus T, Haack M, Schuld A, et al. Bodyweight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312–4PubMedGoogle Scholar
  51. 51.
    Wetterling T, MuBigbrodt H. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999; 19(4): 316–21PubMedCrossRefGoogle Scholar
  52. 52.
    Claus A, Ballen J, DeCuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305PubMedCrossRefGoogle Scholar
  53. 53.
    Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus phenelzine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395–402PubMedCrossRefGoogle Scholar
  54. 54.
    Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712–26PubMedCrossRefGoogle Scholar
  55. 55.
    Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18PubMedCrossRefGoogle Scholar
  56. 56.
    Beasley CM. Safety of olanzapine. J Clin Psychiatry 1997; 15(2): 19–21Google Scholar
  57. 57.
    Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial. Am J Psychiatry 1997; 152(4): 457–65Google Scholar
  58. 58.
    Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. The U.S. Seroquel Study Group. J Clin Psychopharmacol 1996; 16(2): 158–69CrossRefGoogle Scholar
  59. 59.
    Arvanitis LA, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42(233): 246Google Scholar
  60. 60.
    Meats P. Quetiapine (‘Seroquel’): an effective and well tolerated aytpical antipsychotic. Int J Psychiatry Clin Pract 1997; 1: 213–9CrossRefGoogle Scholar
  61. 61.
    Peuskens J, Link CG. A comparison of quetiapine and chlor-promazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265–73PubMedCrossRefGoogle Scholar
  62. 62.
    Gunasekara NS, Spencer CM. Quetiapine: a review of its use in schizophrenia. Drugs 1998; 9: 325–40Google Scholar
  63. 63.
    Peuskens J, Bech P, Moller HJ. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 88: 107–17Google Scholar
  64. 64.
    Loo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997; 170: 18–22PubMedCrossRefGoogle Scholar
  65. 65.
    Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159–77Google Scholar
  66. 66.
    Chou JCY, Serper MR. Ziprasidone: a new highly atypical antipsychotic. Essential Psychopharmacol 1998; 2: 463–85Google Scholar
  67. 67.
    Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173–84PubMedCrossRefGoogle Scholar
  68. 68.
    Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20: 491–505PubMedCrossRefGoogle Scholar
  69. 69.
    Petit M, Raniwalla J, Tweed J, et al. Acomparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallelgroup, double-blind trial. Psychopharmacol Bull 1996; 32: 81–7PubMedGoogle Scholar
  70. 70.
    Leadbetter RA, Vieweg V. Clozapine-induced weight gain. Am J Psychiatry 1990; 147: 1693–4Google Scholar
  71. 71.
    Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight-gain. Pharmacopsychiatry 1995; 28: 35–44PubMedCrossRefGoogle Scholar
  72. 72.
    Kalucy RS. Drug-induced weight gain. Drugs 1980; 19: 268–78PubMedCrossRefGoogle Scholar
  73. 73.
    Robinson RG, McHugh PR, Folstein MF. Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 1975; 12: 59–68PubMedCrossRefGoogle Scholar
  74. 74.
    Wiebe EJ. Weight gain with clozapine treatment. Can J Psychiatry 1993; 38: 70PubMedGoogle Scholar
  75. 75.
    Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35PubMedGoogle Scholar
  76. 76.
    Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60 Suppl. 21: 20–4Google Scholar
  77. 77.
    Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58 Suppl. 10: 45–9Google Scholar
  78. 78.
    Medical Economics Company. Zyprexa™: US package insert for olanzapine. Physician’s Desk Reference 1998; 52nd edition: 1512–6Google Scholar
  79. 79.
    Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999; 19: 99–104CrossRefGoogle Scholar
  80. 80.
    Prakash A, Lamb HM. Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998; 9: 153–75CrossRefGoogle Scholar
  81. 81.
    Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short and long-term use. Acta Psychiatr Scand 2000; 101: 23–7CrossRefGoogle Scholar
  82. 82.
    Stahl SM. Neuropharmacology of obesity: my receptors made me eat it. J Clin Psychiatry 1998; 59: 447–8PubMedCrossRefGoogle Scholar
  83. 83.
    Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuro-psychopharmacology 1996; 14: 87–96CrossRefGoogle Scholar
  84. 84.
    Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57–73PubMedCrossRefGoogle Scholar
  85. 85.
    Green B. Focus on olanzapine. Curr Med Res Opin 1999; 15: 79–85PubMedCrossRefGoogle Scholar
  86. 86.
    Verdoux H, Ganzales B, Takei N, et al. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients. J Affect Disord 1996; 38: 81–7PubMedCrossRefGoogle Scholar
  87. 87.
    Klieser E, Lehmann E, Kinzler E, et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15(1 Suppl. 1): 45S–51SPubMedCrossRefGoogle Scholar
  88. 88.
    Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21: 463–72PubMedCrossRefGoogle Scholar
  89. 89.
    Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine associated with diabetes mellitus. J Clin Psychiatry 1997; 58: 108–11PubMedCrossRefGoogle Scholar
  90. 90.
    Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83PubMedCrossRefGoogle Scholar
  91. 91.
    Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40(5): 438–43PubMedCrossRefGoogle Scholar
  92. 92.
    Ober SK, Hudak RRA. Hyperglycemia and olanzapine. Am J Psychiatry 1999; 156: 970PubMedGoogle Scholar
  93. 93.
    Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294–9PubMedCrossRefGoogle Scholar
  94. 94.
    Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neu-ropharmacol 1998; 21: 245–50Google Scholar
  95. 95.
    Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglyceride levels. Am J Psychiatry 1999; 156: 1270–2PubMedGoogle Scholar
  96. 96.
    Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ 1984; 288: 1401–4PubMedCrossRefGoogle Scholar
  97. 97.
    Walker M, Wannamethee G, Whincup PH, et al. Weight change and risk of heart attack in middle-aged British men. Int J Epidemiol 1995; 24: 694–703PubMedCrossRefGoogle Scholar
  98. 98.
    Sarlio-Lahteenkorva S, Stunkard A, Rissanen A. Psychosocial factors and quality of life in obesity. Int J Obes Relat Metab Disord 1995; 19Suppl. 6: S1–5PubMedGoogle Scholar
  99. 99.
    Franz M, Lis S, Pluddeman K, et al. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422–5PubMedCrossRefGoogle Scholar
  100. 100.
    Tollefson GD, Kuntz AJ. Review of recent clinical studies with olanzapine. Br J Psychiatry 1999; 174 Suppl. 37: 30–5Google Scholar
  101. 101.
    Foster RH, Goa KL. Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999; 6: 611–40CrossRefGoogle Scholar
  102. 102.
    Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999; 60 Suppl. 21: 31–6Google Scholar
  103. 103.
    Baptista T, Lopez ME, Teneud L, et al. Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 1997; 30: 43–54PubMedCrossRefGoogle Scholar
  104. 104.
    Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • James M. Russell
    • 1
  • Joan A. Mackell
    • 2
  1. 1.Department of PsychiatryUniversity of Texas Medical BranchGalvestonUSA
  2. 2.Pfizer Inc.New YorkUSA

Personalised recommendations